Aptahem AB (publ) (NGM:APTA)

Market Cap	20.26M +68.5%
Revenue (ttm)	2.59M -31.5%
Net Income	-6.49M
EPS	-0.38
Shares Out	20.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,252
Average Volume	35,109
Open	0.8580
Previous Close	0.9660
Day's Range	0.8580 - 0.9680
52-Week Range	0.5600 - 2.4000
Beta	0.44
RSI	50.49
Earnings Date	Feb 12, 2026

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2025, Aptahem AB's revenue was 2.59 million, a decrease of -31.47% compared to the previous year's 3.77 million. Losses were -6.49 million, -24.26% less than in 2024.